Claims for Patent: 11,649,217

Summary for Patent: 11,649,217

Title:	Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Abstract:	The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
Inventor(s):	Minhua Chen, Yanfeng Zhang, Jinqiu WANG, Xiaoyu Zhang
Assignee:	GlaxoSmithKline Intellectual Property No 2 Ltd
Application Number:	US17/174,006
Patent Claims:	1. A composition of crystalline Form CS1 of N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine, wherein the X-ray powder diffraction pattern of Form CS1 shows characteristic peaks at 2theta values of 6.4°±0.2°, 7.5°±0.2°, and 7.9°±0.2° using CuKα radiation, and wherein the content of other crystalline forms is less than 10% (w/w). 2. The composition according to claim 1, wherein the X-ray powder diffraction pattern of Form CS1 shows one or more characteristic peaks at 2theta values of 17.2°±0.2°, 21.0°±0.2°, 24.0°±0.2°, and 19.3°±0.2° using CuKα radiation. 3. The composition according to claim 1, wherein the X-ray powder diffraction pattern of Form CS1 is substantially as depicted in FIG. 1 . 4. The composition according to claim 1, wherein the Form CS1 has an endothermic peak at around 242° C. as measured by differential scanning calorimetry using a heating rate of 10° C./min and a purge gas of nitrogen. 5. The composition according to claim 1, wherein the chemical purity of Form CS1 is higher than 99%. 6. The composition according to claim 5, wherein the chemical purity remains substantially unchanged when the composition is stored under conditions of 60° C. 75% RH for 3 months. 7. A composition of crystalline Form CS9 of N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine, wherein the X-ray powder diffraction pattern of Form CS9 shows characteristic peaks at 2theta values of 4.6°±0.2°, 6.6°±0.2°, and 21.1°±0.2° using CuKα radiation, and wherein the content of other crystalline forms is less than 10% (w/w). 8. The composition according to claim 7, wherein the X-ray powder diffraction pattern of Form CS9 shows one or more characteristic peaks at 2theta values of 9.4°±0.2°, 20.2°±0.2°, and 24.2°±0.2° using CuKα radiation. 9. The composition according to claim 7, wherein the X-ray powder diffraction pattern of Form CS9 is substantially as depicted in FIG. 6 . 10. The composition according to claim 7, wherein Form CS9 has a first endothermic peak at around 145° C. and a second endothermic peak at around 237° C. as measured by differential scanning calorimetry using a heating rate of 10° C./min and a purge gas of nitrogen. 11. The composition according to claim 7, wherein the chemical purity of Form CS9 is higher than 99%. 12. The composition according to claim 11, wherein the chemical purity remains substantially unchanged when the composition is stored under conditions of 60° C./75% RH for 1 month. 13. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the composition of crystalline Form CS1 according to claim 1, and pharmaceutically acceptable carriers, diluents or excipients. 14. A pharmaceutical composition according to claim 13, wherein the crystalline form does not change following one-month storage at 40° C./75% RH. 15. A method of treating anemia, comprising administering to a subject in need thereof a therapeutically effective amount of the composition of crystalline Form CS1 according to claim 1. 16. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of the composition of crystalline Form CS9 according to claim 7, and pharmaceutically acceptable carriers, diluents or excipients. 17. A pharmaceutical composition according to claim 16, wherein the crystalline form does not change following one-month storage at 40° C./75% RH. 18. A method of treating anemia, comprising administering to a subject in need thereof a therapeutically effective amount of the composition of crystalline Form CS9 according to claim 7.